World's Best Scientists 2026 revealed!
Award Badge
Medicine
Australia
2023

D-Index & Metrics

Medicine

D-Index
128
Citations
70233
World Ranking
2681
National Ranking
77

John F. Seymour publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John F. Seymour sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 907 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John F. Seymour D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John F. Seymour sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Australia Leader Award

Overview

John F. Seymour is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research primarily spans the field of Medicine, with a strong focus on several key subfields including Genetics, Pathology and Forensic Medicine, Oncology, Hematology, and Immunology.

The main topics covered in their body of work include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Myeloid Leukemia Treatments, Immunodeficiency and Autoimmune Disorders, Viral-associated cancers and disorders, and Advanced Breast Cancer Therapies.

The scientist has published extensively in a variety of journals, with frequent contributions to the following venues:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia & lymphoma/Leukemia and lymphoma

Notable recent papers authored or co-authored by John F. Seymour include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial (2021, Journal of Clinical Oncology)
  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020, Annals of Oncology)
  • Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study (2020, Journal of Clinical Oncology)
  • Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia (2023, New England Journal of Medicine)

Collaborations have been frequent with several researchers, including:

  • Constantine S. Tam
  • Chan Y. Cheah
  • Piers Blombery
  • Arnon P. Kater
  • Mary Ann Anderson

Best Publications

  • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

    Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Hervé Dombret;John F. Seymour;Aleksandra Butrym;Agnieszka Wierzbowska

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

  • Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

  • Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Lauren E. Abrey;Tracy T. Batchelor;Andrés J.M. Ferreri;Mary Gospodarowicz

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Pulmonary alveolar proteinosis: progress in the first 44 years.

    John F. Seymour;Jeffrey J. Presneill

  • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer

  • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

    Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

  • Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Matthew S. Davids;Andrew W. Roberts;Andrew W. Roberts;John F. Seymour;John F. Seymour;John M. Pagel

  • Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

    Robert Marcus;Andrew Davies;Kiyoshi Ando;Wolfram Klapper

  • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

    Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

Frequent Co-Authors

Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Constantine S. Tam
Constantine S. Tam University of Melbourne
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
H. Miles Prince
H. Miles Prince Peter MacCallum Cancer Centre
Andrew Grigg
Andrew Grigg Austin Hospital
Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
David C. S. Huang
David C. S. Huang Walter and Eliza Hall Institute of Medical Research
Pierre Fenaux
Pierre Fenaux Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA often opens up a diverse range of career pathways, many of which can also be pursued through online education. For those looking to enter healthcare quickly or work behind the scenes, earning a medical billing and coding certification online can lead to rewarding roles in healthcare administration with flexible work options.

Aspiring nurses have plenty of choices too. There are online nurse practitioner programs for those who want to advance their clinical skills and gain independent practice rights. If affordability is a key consideration, students can find cheap online nursing programs that provide quality education without a high price tag.

For experienced nurses aiming for leadership, teaching, or research roles, pursuing phd nursing programs online allows for greater flexibility while balancing work and study. These online pathways make advanced healthcare education more accessible, helping support the growing demand for skilled professionals across the medical field.

Best Scientists Citing John F. Seymour

Trending Scientists

Recently Published Articles